Acadia Healthcare Company (ACHC) Q2 2025 Earnings Call August 06, 2025 09:00 AM ET Speaker0Good day, and welcome to Acadia Healthcare's Second Quarter of twenty twenty five Earnings Call. All participants will be in a listen only mode for the duration of the call. After today's presentation, there will be an opportunity to ask questions. On today's call, we ask that you please limit yourself to one question and one follow-up during Q and A. Also, please be aware that today's call is being recorded.I'd now l ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2025 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ____________ to ____________ Commission File Number: 001-35331 Acadia Healthcare Company, Inc. (Exact name of registrant as specified in its charter) (State or ...

Exhibit 99 ACADIA HEALTHCARE REPORTS SECOND QUARTER 2025 RESULTS Provides Updated Guidance for 2025; Announces Chief Financial Of icer Transition FRANKLIN, Tenn. (August 5, 2025) – Acadia Healthcare Company, Inc. ("Acadia" or the "Company") (NASDAQ: ACHC) today announced financial results for the second quarter ended June 30, 2025. Second Quarter 2025 Highlights Adjusted income attributable to Acadia and Adjusted EBITDA are non-GAAP financial measures. A reconciliation of all non- GAAP financial measures in ...

Group 1 - Acadia Healthcare Company, Inc. (ACHC) is experiencing significant attention from investors due to high implied volatility in its options market, particularly the Jun 20, 2025 $65 Call option [1] - Implied volatility indicates the market's expectation of future price movement, suggesting that investors anticipate a substantial price change or an upcoming event that could trigger a rally or sell-off [2] - Acadia Healthcare currently holds a Zacks Rank 3 (Hold) in the Medical - Hospital industry, which is in the top 35% of the Zacks Industry Rank, but analysts have not increased earnings estimates for the current quarter, with a consensus estimate dropping from 77 cents to 71 cents per share [3] Group 2 - The high implied volatility surrounding Acadia Healthcare may indicate a developing trading opportunity, as options traders often seek to sell premium on options with high implied volatility to capture decay [4]

Acadia Healthcare Company (ACHC) 2025 Conference Summary Industry Overview - Acadia Healthcare is one of the largest behavioral health providers in the US, operating a network of 270 facilities with approximately 12,000 beds across 39 states and Puerto Rico, serving over 80,000 patients daily [6][7][8]. Key Financial Performance - The company reported that revenue, EBITDA, volume, revenue per day, and margins were all in line with guidance, with EBITDA at the high end of the range [2][3]. - Acadia added 378 newly licensed beds in Q1 and reaffirmed its full-year financial guidance for both revenue and adjusted EBITDA [3][4]. Demand and Growth Outlook - Consistent demand is observed across all four lines of business, with a significant opportunity in the behavioral health sector due to an estimated 75,000 additional beds needed in the US to meet demand [6][7]. - The company is in a period of record growth, expecting to add 800 to 1,000 beds in 2025, with nearly half already achieved in Q1 [10][11]. - The Comprehensive Treatment Centers (CTCs) segment is expected to grow mid-single digits over the next few years, with a strong demand for opioid use disorder treatment [9][15]. Operational Insights - The average cost per new facility bed is estimated at $500,000 to $550,000, with a target breakeven period of 12 to 13 months and expected maturity occupancy of 80% to 85% within three to five years [12][13]. - The company is focused on tuck-in M&A to acquire existing CTCs, which is a fragmented part of healthcare, enhancing growth and efficiency [18]. Policy and Regulatory Environment - Acadia is monitoring the implications of the opioid settlement funds, with $50 billion available but only a small percentage reaching states and counties [19][20]. - The company is optimistic about the potential impact of the reconciliation bill on access to high acuity mental health care, which could mitigate costs in other healthcare areas [24][25]. Pricing and Revenue Guidance - The company anticipates low single-digit pricing growth, with supplemental payments being a significant factor in revenue projections [46][47]. - For 2025, Acadia expects revenue growth of 6%, but EBITDA is projected to decline year-over-year due to various headwinds, including supplemental payment reductions and underperforming facilities [52][53]. Challenges and Risks - The company faces challenges from underperforming facilities, which are expected to impact EBITDA by approximately $20 million for the year [34][38]. - There is ongoing concern regarding potential policy changes and their impact on Medicaid access and reimbursement rates [26][30]. Conclusion - Acadia Healthcare is positioned for growth in the behavioral health sector, with strong demand and strategic plans for bed additions and acquisitions. However, it must navigate regulatory challenges and operational headwinds to achieve its financial targets [41][44].

Core Viewpoint - Acadia Healthcare Company, Inc. (ACHC) reported mixed financial results for the first quarter, with adjusted earnings per share beating estimates but showing a significant year-over-year decline, while total revenues showed slight growth [1][2]. Financial Performance - Adjusted first-quarter earnings were 40 cents per share, exceeding the Zacks Consensus Estimate by 14.3%, but down 52.4% year over year [1]. - Total revenues increased by 0.3% year over year to $770.5 million, aligning with consensus expectations [1]. - Same-facility revenues rose 2.1% year over year to $759.7 million, although this fell short of the estimated $763.1 million [3]. - Total adjusted EBITDA decreased by 22.8% year over year to $134.2 million, slightly below the estimate of $134.9 million [4]. Operational Metrics - Patient days improved by 2.2% year over year, contributing to increased admissions, which grew by 2.1% [3]. - Revenue per patient day declined by 0.2% year over year, missing the growth estimate of 2% [3][4]. - Total expenses rose by 13.1% year over year to $757 million, exceeding the estimate of $744.6 million, driven by higher salaries, wages, benefits, and operating costs [5]. Cash and Debt Position - As of March 31, 2025, cash and cash equivalents increased to $91.2 million from $76.3 million at the end of 2024 [5]. - Total assets grew to $6.1 billion, while long-term debt rose to $2.2 billion from $1.9 billion at the end of 2024 [6]. - Total equity decreased by 1% to $3 billion, with a net leverage ratio of approximately 3.2 [6]. Share Repurchase and Guidance - Management authorized a share repurchase program for up to $300 million, with $47.3 million worth of shares repurchased in the first quarter [7]. - The company reaffirmed its 2025 guidance, projecting revenues between $3.3 billion and $3.4 billion, adjusted EBITDA between $675 million and $725 million, and adjusted EPS between $2.50 and $2.80 [8]. Future Projections - Interest expenses are expected to remain between $130 million and $140 million, with depreciation and amortization expenses projected at $175 million to $185 million [9]. - Operating cash flows are forecasted to be in the range of $460 million to $510 million, with expansion capital expenditures anticipated between $525 million and $575 million [9]. - Management estimates bed additions between 800 and 1,000 in 2025 [10].

Financial Data and Key Metrics Changes - First quarter revenue was $770.5 million, slightly above the midpoint of the guidance range of $765 million to $775 million [6] - Adjusted EBITDA for the first quarter was $134.2 million, near the high end of the guidance range of $130 million to $135 million [6] - Same facility patient days grew by 2.2% in the first quarter, impacted by an unfavorable leap year effect of approximately 110 basis points [6][15] - Adjusted EBITDA margin was 17.4% for the first quarter [16] Business Line Data and Key Metrics Changes - Same facility revenue grew by 2.1% year-over-year, driven by patient day growth of 2.2% [15] - Same facility adjusted EBITDA was $191.6 million, with an adjusted EBITDA margin of 25.2% [17] - Start-up losses related to new facilities were higher year-over-year and sequentially, reflecting an increase in newly constructed facilities [16] Market Data and Key Metrics Changes - Acadia added 378 new beds in the first quarter, including 90 beds to existing facilities and 288 beds from two new facilities [7] - The company expects to add between 800 to 1,000 total beds for the full year 2025 [18] Company Strategy and Development Direction - Acadia's strategy focuses on high-quality care and clinical health outcomes, with a commitment to quality and safety as foundational elements [10] - The company aims to bridge the gap between physical and behavioral health care, enhancing relationships with referral sources and joint venture partners [7] - Acadia plans to continue expanding its market reach, with expectations to add between 600 to 800 beds annually from 2026 to 2028 [8][21] Management's Comments on Operating Environment and Future Outlook - Management expressed optimism about the demand for behavioral health services, particularly for higher acuity patients [39] - The company remains engaged in policy discussions to strengthen the behavioral health care system and expects continued support for essential care [12] - Management acknowledged the challenges posed by underperforming facilities but indicated that improvements are expected over time [17][19] Other Important Information - As of March 31, 2025, Acadia had $91.2 million in cash and cash equivalents and approximately $900 million available under its revolving credit facility [18] - The company repurchased approximately 1.6 million shares during the first quarter for a total of $47.3 million [18] Q&A Session Summary Question: Can you provide perspective on the progression of EBITDA and seasonality of the business this year? - Management highlighted several moving parts affecting EBITDA, including the timing of supplemental payments and the impact of start-up costs from new beds [25][28] Question: What are you seeing in Medicaid rate updates? - Management noted stable underlying rate growth and a cautious approach to assumptions due to policy uncertainties [32][34] Question: How is the broader demand environment for behavioral health? - Management indicated consistent demand for services, particularly for higher acuity patients, and ongoing efforts to meet that demand through new facilities and bed additions [39][41] Question: What is the expected return target for new facilities? - Management emphasized a disciplined approach to capital deployment, ensuring returns exceed the cost of capital [65][66] Question: How should we think about legal expenses moving forward? - Management is actively cooperating with ongoing investigations, and while it's difficult to predict future legal costs, significant preliminary work is being undertaken [73][74] Question: Can you provide guidance on Q2's percentage of annual guidance? - Management refrained from providing specific Q2 guidance but noted that supplemental payments, particularly from the Tennessee program, would be a significant swing factor [79][80] Question: What is happening with specialty revenue? - Management acknowledged a year-over-year decline in specialty revenue and indicated ongoing efforts to address this issue [104]

Financial Data and Key Metrics Changes - First quarter revenue for 2025 was $770.5 million, slightly above the midpoint of the guidance range of $765 million to $775 million [5][14] - Adjusted EBITDA for the first quarter was $134.2 million, near the high end of the guidance range of $130 million to $135 million, reflecting an adjusted EBITDA margin of 17.4% [5][15] - Same facility patient days grew by 2.2% in the first quarter, with same facility revenue growth of 2.1% compared to the first quarter of 2024 [5][14] Business Line Data and Key Metrics Changes - The company added 378 new beds in the first quarter, including 90 beds to existing facilities and 288 beds from two new facilities [6] - Same facility adjusted EBITDA was $191.6 million, with an adjusted EBITDA margin of 25.2% [16] - Start-up losses related to new facilities were higher year-over-year and sequentially, reflecting an increase in newly constructed facilities [15] Market Data and Key Metrics Changes - The company expects to add between 800 to 1,000 total beds for the full year 2025, with a solid pipeline of potential opportunities in attractive markets [7][18] - The company anticipates Medicaid supplemental payments to be flat to up $15 million in 2025 on a net basis [19] Company Strategy and Development Direction - Acadia's strategy focuses on high-quality care and clinical health outcomes, with a commitment to quality and safety as foundational elements [10][12] - The company aims to bridge the gap between physical and behavioral health care, maintaining strong relationships with referral sources and joint venture partners [6] - The company is engaged in policy advocacy to strengthen the behavioral health care system, emphasizing the importance of government support for underserved populations [12] Management's Comments on Operating Environment and Future Outlook - Management expressed optimism about the demand for behavioral health services, particularly for higher acuity patients, and noted consistent demand across various lines of business [38] - The company acknowledged challenges from underperforming facilities but expects to see improvements as they comp over headwinds in the fourth quarter of 2025 [19] - Management remains cautious about rate growth due to uncertainties in the policy environment but noted stable underlying rate growth [35] Other Important Information - As of March 31, 2025, the company had $91.2 million in cash and cash equivalents and approximately $900 million available under its revolving credit facility [18] - The company repurchased approximately 1.6 million shares during the first quarter for a total of $47.3 million [18] Q&A Session Summary Question: Can you provide perspective on the progression of EBITDA and seasonality this year? - Management highlighted several moving parts affecting Q1, including the timing of supplemental payments and the highest level of start-up costs, leading to a steeper ramp in EBITDA as the year progresses [25][28] Question: What are you seeing in Medicaid rate updates? - Management noted ongoing positive discussions with payer partners and maintained a conservative outlook on rate growth due to policy uncertainties, but underlying rate growth has been stable [33][35] Question: How is the broader demand environment for behavioral health? - Management indicated consistent demand for higher acuity patients across various business lines, with ongoing efforts to meet that demand through new facilities and bed additions [38] Question: What is the expected return target for new facilities? - The company applies a disciplined approach to capital deployment, ensuring that all projects meet required return thresholds, with sensitivity analyses incorporated for future projects [63][66] Question: How should we think about legal expenses moving forward? - Management is actively cooperating with ongoing investigations and anticipates that legal costs may normalize as preliminary work is completed [70][72] Question: What is happening with specialty revenue? - Management acknowledged that closures of specialty facilities have contributed to a decline in specialty revenue, but they are working to stabilize and grow this line moving forward [97][98]

Core Viewpoint - Acadia Healthcare reported quarterly earnings of $0.40 per share, exceeding the Zacks Consensus Estimate of $0.35 per share, but down from $0.84 per share a year ago [1][2] Financial Performance - The company achieved revenues of $770.51 million for the quarter ended March 2025, aligning with the Zacks Consensus Estimate and showing a slight increase from $768.05 million year-over-year [3] - Acadia Healthcare has surpassed consensus EPS estimates three times over the last four quarters, but has only topped revenue estimates once in the same period [2][3] Stock Performance - The stock has declined approximately 39.9% since the beginning of the year, contrasting with the S&P 500's decline of 3.8% [4] - The current Zacks Rank for Acadia Healthcare is 4 (Sell), indicating expectations of underperformance in the near future [7] Earnings Outlook - The consensus EPS estimate for the upcoming quarter is $0.77 on revenues of $852.98 million, and for the current fiscal year, it is $2.68 on revenues of $3.33 billion [8] - The trend of estimate revisions for Acadia Healthcare has been unfavorable leading up to the earnings release [7] Industry Context - The Medical - Hospital industry, to which Acadia Healthcare belongs, is currently ranked in the top 40% of over 250 Zacks industries, suggesting a favorable environment compared to the bottom 50% [9]

Financial Performance - Revenue for Q1 2025 totaled $770.5 million, a slight increase from $768.1 million in Q1 2024[8] - Adjusted EBITDA for Q1 2025 was $134.2 million, reflecting a year-over-year impact of $5 million due to the closure of one facility[8] - Net income attributable to Acadia was $8.4 million, or $0.09 per diluted share, compared to $76.4 million, or $0.83 per diluted share in Q1 2024[8][22] - Revenue for same facilities increased by 2.1% to $759,697,000 in Q1 2025 from $744,422,000 in Q1 2024[29] - Adjusted EBITDA decreased by 9.0% to $191,605,000 in Q1 2025 from $210,579,000 in Q1 2024[29] - Total facility revenue showed a slight increase of 0.3%, reaching $770,505,000 in Q1 2025 compared to $768,051,000 in Q1 2024[29] - Adjusted income attributable to Acadia Healthcare Company, Inc. was $36,929,000 in Q1 2025, down from $77,293,000 in Q1 2024[34] - Revenue per patient day slightly decreased by 0.2% to $994 in Q1 2025 from $996 in Q1 2024[29] Operational Highlights - The company added a total of 378 newly licensed beds in Q1 2025, including 90 beds to existing facilities and 288 beds to new facilities[6][8] - Acadia operates 270 behavioral healthcare facilities with approximately 12,000 beds, serving over 82,000 patients daily[16] - The company affirmed its 2025 financial guidance, projecting revenue between $3.3 billion and $3.4 billion and Adjusted EBITDA between $675 million and $725 million[13] - Acadia's strategic growth includes the addition of seven new comprehensive treatment centers, expanding its market reach to 170 CTCs across 33 states[7] Cash Flow and Capital Management - Cash and cash equivalents as of March 31, 2025, were $91.2 million, with an additional $901.6 million available under its revolving credit facility[10] - Cash provided by operating activities was $11,477,000 in Q1 2025, a recovery from a cash outflow of $321,285,000 in Q1 2024[26] - Cash paid for acquisitions in Q1 2025 was $8,594,000, down from $50,353,000 in Q1 2024[26] - The company reported a net cash increase of $14,931,000 in Q1 2025, contrasting with a decrease of $22,770,000 in Q1 2024[26] - Acadia repurchased 1,602,688 shares for a total of $47.3 million during Q1 2025[12] Costs and Expenses - Government investigations costs increased significantly to $31.011 million in Q1 2025 from $0.481 million in Q1 2024[51] - Total transaction, legal, and other costs rose to $31.072 million in Q1 2025 compared to $2.847 million in Q1 2024[51] - Termination and restructuring costs were $2.166 million in Q1 2025, a decrease from $(3.400) million in Q1 2024[51] - Legal, accounting, and other acquisition-related costs showed a net expense of $(2.105) million in Q1 2025, down from $4.757 million in Q1 2024[51] - Management transition costs were recorded at $1.009 million in Q1 2024, with no costs reported in Q1 2025[51] Tax and Adjustments - The income tax effect of adjustments to income was based on tax rates of 24.1% for Q1 2025 and 22.2% for Q1 2024[55] - The company believes that excluding certain costs from Adjusted EBITDA helps investors understand ongoing operating results better[52] - General and administrative costs are excluded from Total Facility Adjusted EBITDA to provide clearer insights into core operations[53] - The company focuses on Same Facility Adjusted EBITDA to measure financial performance of existing facilities, excluding newly developed or recently acquired facilities[54] - The company incurred debt extinguishment costs in Q1 2025 related to refinancing, which are excluded from Adjusted EBITDA[52]